Last reviewed · How we verify
AD-221A and AD-221B — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
AD-221A and AD-221B (AD-221A and AD-221B) — Addpharma Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AD-221A and AD-221B TARGET | AD-221A and AD-221B | Addpharma Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AD-221A and AD-221B CI watch — RSS
- AD-221A and AD-221B CI watch — Atom
- AD-221A and AD-221B CI watch — JSON
- AD-221A and AD-221B alone — RSS
Cite this brief
Drug Landscape (2026). AD-221A and AD-221B — Competitive Intelligence Brief. https://druglandscape.com/ci/ad-221a-and-ad-221b. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab